Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.

Marina Elena Cazzaniga,Paolo Pronzato,Francesco Schettini,Lucia Del Mastro,Maria Riemma,Massimiliano Alù,Anna Turletti,Monica Giordano,P. Pugliese,Claudia De Angelis,Ornella Garrone,Paolo Marchetti,Ferdinando Riccardi,Antonio Bernardo,Lorenzo Livi,Alessandra Fabi,Cristiana Taverniti,Sabino De Placido,Giorgio Mustacchi

Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.

2019

Marina Elena Cazzaniga
Paolo Pronzato
Francesco Schettini
Lucia Del Mastro
Maria Riemma
Massimiliano Alù
Anna Turletti
Monica Giordano
P. Pugliese
Claudia De Angelis
Ornella Garrone
Paolo Marchetti
Ferdinando Riccardi
Antonio Bernardo
Lorenzo Livi
Alessandra Fabi
Cristiana Taverniti
Sabino De Placido
Giorgio Mustacchi

e12528Background: Pts with ABC have a diverse clinical course and OS rates vary significantly among pts. New strategies had potentially changed the natural history of these pts, however data from c...

Keywords:

Progression-free survival
Oncology
Breast cancer
Pathology
Internal medicine
Medicine
overall survival
clinical course
Cancer
advanced breast
Natural history

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations